Pre-made Lacutamab benchmark antibody ( Whole mAb, anti-KIR3DL2/CD158k therapeutic antibody, Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lacutamab biosimilar, Whole mAb, Anti-KIR3DL2/CD158k Antibody: Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lacutamab is a humanised version of anti KIR3DL2 monoclonal antibody clone #1, and has been shown to have potent activity against KIR3DL2-positive tumours.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-290-1mg	1mg	3090
GMP-Bios-ab-290-10mg	10mg	Inquiry
GMP-Bios-ab-290-100mg	100mg	Inquiry
GMP-Bios-ab-290-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lacutamab biosimilar, Whole mAb, Anti-KIR3DL2/CD158k Antibody: Anti-3DL2/CD158K/KIR-3DL2/NKAT-4/NKAT4/NKAT4B/p140 therapeutic antibody
INN Name	Lacutamab
Target	CD158k
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	University of Genoa;Innate Pharma
Conditions Approved	na
Conditions Active	Mycosis fungoides;Peripheral T-cell lymphoma;Sezary syndrome
Conditions Discontinued	na
Development Tech	na